Sightsavers Logo
Research centre
  • Home
  • About us
  • Research approach
  • Research studies and publications
  • Evidence gap maps
Join in:
  • Join in: Facebook
  • Join in: Twitter
  • Join in: Instagram
  • Join in: LinkedIn
  • Join in: YouTube
  • Global
  • Close search bar
    Donate
    • Home
    • About us
    • Research approach
    • Research studies and publications
    • Evidence gap maps

    Could intensive blood pressure control really reduce diabetic retinopathy outcomes? Evidence from meta-analysis and trial sequential analysis from randomized controlled trials

    Methodological quality of the review: Medium confidence

    Author: Zhou JB, Song ZH, Bai L, Zhu XR, Li HB, Yang JK

    Region: United Stated of America (USA), Italy, Slovenia, Denmark, United Kingdom (UK) and Canada.

    Sector: Diabetic retinopathy

    Sub-sector: Risk factor

    Equity focus:  None specified

    Review type: Other review

    Quantitative synthesis method: Meta-analysis

    Qualitative synthesis method: Not applicable

    Background:

    Objectives:

    To explore the accumulated evidence concerning the effect of intensive blood pressure control on the incidence and progression of diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and macular edema (MA).

    Main findings:

    Eight trials randomizing 6,989 patients were included in the review: 3,749 vs. 3,240 were in each arm (intensive versus conventional). Authors attributed low risk of bias to all trials. Authors reported that intensive blood pressure control supported a 17% reduction in the incidence of DR (relative risk 0.83, 95% confidence interval 0.72–0.95). Authors’ trial sequential analyses confirmed that sufficient evidence indicated a relative risk reduction above 17% for the incidence of DR when intensive blood pressure control was targeted.

    Authors reported no heterogeneity within studies (I2 = 0%; P = 0.56). In addition, authors reported no statistically significant effect was found for intensive blood pressure targeting on the progress of DR (relative risk 0.94, 95% confidence interval 0.81–1.08). Authors noted that trial sequential analysis (TSA) showed that insufficient evidence had been found, although the Z value line appeared to have a tendency of approaching the futility boundaries. In addition, findings from authors analysis showed that there were no statistically significant effects on the incidence of PDR and ME (TSA-adjusted CI 0.84–1.12).

    Authors concluded that intensive blood pressure control reduced the relative risk of incidence of DR by 17%; the available data were insufficient to prove or refute a relative risk reduction for the progression of DR or incidence of PDR and ME at a magnitude of 15%.

    Authors note that this study findings for daily clinical practice should be emphasized, and in addition, they state that understanding whether diabetic individuals have a lower risk of DR with the strict blood pressure targets will help diabetologists to provide effective clinical counseling for patients. Blood pressure optimization should be done in primary care or by a diabetologist before the patients even see the ophthalmologist.

    Methodology: 

    Inclusion criteria consisted of randomized controlled trials (RCTs) investigating the effect of strict blood pressure targeting on the incidence, progression of DR, or incidence of PDR and ME.

    Authors searched the following databases MEDLINE, EMBASE, and the Cochrane Controlled Trials Register for articles from inception to April 2018 using a search strategy as follows: [diabetic retinopathy, proliferative diabetic retinopathy (PDR), macular edema, diabetic maculopathy, retinal disorders, retinal disease, diabetic eye disease, or vision loss], (randomized, random, placebo-controlled, double-blind), (hypertension or blood pressure) and (angiotensin II type 1 receptor blockers, adrenergic alpha antagonist, adrenergic beta antagonists, diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, antihypertensive agents).

    Two authors independently screened studies for inclusion and extracted data of included studies. Authors note diving included trials into those with low and high risk of bias according to Cochrane Handbook risk of bias tool.

    Authors assessed the within- and between-study variation or heterogeneity by testing Cochran’s Q statistic. Authors quantified heterogeneity with I2 metric, they estimated pooled OR using fixed effects and random effects models. Random effects was used when heterogeneity was present among studies. Authors note assessing for publication bias using the Egger’s regression test. A trial sequential analysis was conducted by the authors.

    Applicability/external validity:

    Authors did not assess applicability/external validity of findings.

    Geographic focus:

    Authors included studies from high income settings and it is not clear if authors included studies conducted in low- and middle-income countries.

    Summary of quality assessment:

    Overall, there is medium confidence in the conclusions about the effects of this review. Although authors used appropriate methods to screen studies and extract data of included studies, authors did not conduct a thorough search of the literature to ensure all eligible RCTs were identified and included in the review.

    Publication Source:

    Zhou JB, Song ZH, Bai L, Zhu XR, Li HB, Yang JK. Could Intensive Blood Pressure Control Really Reduce Diabetic Retinopathy Outcomes? Evidence from Meta- Analysis and Trial Sequential Analysis from Randomized Controlled Trials. Diabetes Ther. 2018 Oct;9(5):2015-2027.

    source

    Sightsavers Logo
    Research centre
    • Join in:
    • Join in: Facebook
    • Join in: X
    • Join in: Instagram
    • Join in: LinkedIn
    • Join in: YouTube

    Protecting sight, fighting disease and promoting equality for all

  • Accessibility
  • Sightsavers homepage
  • Our policies
  • Media centre
  • Contact us
  • Jobs
  • Cookies and privacy Terms and conditions Modern slavery statement Safeguarding

    © 2025 by Sightsavers, Inc., Business Address for all correspondence: One Boston Place, Suite 2600, Boston, MA 02108.

    Our website uses cookies

    To make sure you have a great experience on our site, we’d like your consent to use cookies. These will collect anonymous statistics to personalise your experience.

    Manage preferences

    You have the option to enable non-essential cookies, which will help us enhance your experience and improve our website.

    Essential cookiesAlways on

    These enable our site to work correctly, for example by storing page settings. You can disable these by changing your browser settings, but some parts of our website will not work as expected.

    Analytics cookies

    To improve our website, we’d like to collect anonymous data about how you use the site, such as which pages you read, the device you’re using, and whether your visit includes a donation. This is completely anonymous, and is never used to profile individual visitors.

    Advertising cookies

    To raise awareness about our work, we’d like to show you Sightsavers adverts as you browse the web. By accepting these cookies, our advertising partners may use anonymous information to show you our adverts on other websites you visit. If you do not enable advertising cookies, you will still see adverts on other websites, but they may be less relevant to you. For info, see the Google Ads privacy policy.